Logo

EWTX

Edgewise Therapeutics, Inc.

EWTX

Edgewise Therapeutics, Inc. • NASDAQ
$26.04 ▲ 2.04% (+0.52)
Market Cap $2.76 B
52w High $35.50
52w Low $10.60
Dividend Yield 0%
P/E -16.59
Volume 365.20K
Outstanding Shares 105.87M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $46.858M ▲ $-40.666M ▼ 0% $-0.39 ▼ $-40.143M ▲
Q2-2025 $0 $42.61M ▼ $-36.115M ▲ 0% $-0.34 ▲ $-42.043M ▲
Q1-2025 $0 $45.959M ▲ $-40.798M ▼ 0% $-0.43 ▼ $-45.405M ▼
Q4-2024 $0 $45.54M ▲ $-39.662M ▼ 0% $-0.42 ▼ $-44.911M ▼
Q3-2024 $0 $40.432M $-34.129M 0% $-0.36 $-39.83M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $563.34M ▼ $583.466M ▼ $24.819M ▲ $558.647M ▼
Q2-2025 $593.992M ▲ $613.334M ▲ $24.263M ▼ $589.071M ▲
Q1-2025 $436.387M ▼ $454.391M ▼ $24.672M ▼ $429.719M ▼
Q4-2024 $470.17M ▼ $486.817M ▼ $27.601M ▲ $459.216M ▼
Q3-2024 $492.536M $511.282M $22.405M $488.877M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-40.666M ▼ $-34.776M ▼ $35.716M ▲ $1.659M ▼ $2.599M ▲ $-34.865M ▼
Q2-2025 $-36.115M ▲ $-32.582M ▲ $-162.166M ▼ $188.231M ▲ $-6.517M ▼ $-32.632M ▲
Q1-2025 $-40.798M ▼ $-37.866M ▼ $43.898M ▲ $2.223M ▼ $8.255M ▲ $-37.91M ▼
Q4-2024 $-39.662M ▼ $-26.957M ▲ $20.922M ▼ $2.895M ▼ $-3.14M ▼ $-27.231M ▲
Q3-2024 $-34.129M $-27.374M $25.362M $3.333M $1.321M $-27.894M

Five-Year Company Overview

Income Statement

Income Statement Edgewise is still a pure research company with no product revenue yet. The income statement is driven almost entirely by R&D and related operating costs, which have grown as programs move deeper into the clinic. Losses have widened over time, which is typical for a clinical‑stage biotech scaling trials but means the business is far from break-even. Per‑share losses reflect this steady investment phase rather than any current commercial weakness, because there is no commercial business yet.

Balance Sheet

Balance Sheet The balance sheet shows a development‑stage biotech with a reasonable asset base and very little financial debt. Shareholders’ equity has moved from negative to clearly positive, suggesting that past capital raises have strengthened the company’s foundation. Cash represents a meaningful portion of total assets, though not enough to ignore the need for future funding if current spending continues. Overall, the structure looks clean and not heavily leveraged, but the company remains dependent on the capital markets to fund long, expensive clinical programs.

Cash Flow

Cash Flow Cash flows reflect a classic cash‑burn profile: money consistently going out to fund research and trials, with nothing yet coming in from products. Operating cash outflows have grown as the pipeline expanded, and free cash flow is solidly negative. Capital spending is modest, which fits a model focused more on people, labs, and trials than on heavy equipment. The key risk is how long existing cash can support the current burn rate before new financing is needed, especially with several major trials ahead.

Competitive Edge

Competitive Edge Edgewise is trying to carve out a specialized niche in muscle diseases, where treatment options are limited and medical need is high. Its approach—oral small‑molecule drugs that protect or modulate muscle and heart function—differs from many competitors focused on gene therapies or protein replacement. This gives the company a differentiated story, but it also competes against larger, well‑funded players in dystrophinopathies and cardiomyopathy. The real proof of its competitive position will depend on future trial results, regulatory views, and how convincingly its drugs improve outcomes versus existing and emerging treatments.

Innovation and R&D

Innovation and R&D The company’s core strength is its deep focus on muscle biology and an integrated discovery engine that quickly cycles between chemistry and biology. Lead programs like sevasemten for Duchenne and Becker muscular dystrophy and EDG‑7500 for hypertrophic cardiomyopathy target the mechanics of muscle damage and heart function in a novel way. Early and mid‑stage data have been encouraging, and the pipeline now extends into heart failure and broader cardiometabolic ideas. However, this innovation strategy is highly execution‑dependent: a few pivotal trials and regulatory decisions over the next several years will have an outsized impact on the value of the entire R&D portfolio.

Summary

Edgewise is an early‑stage, science‑driven biotech with no revenue today and a clear focus on rare muscle and heart diseases. Financially, it runs steady operating losses and burns cash to advance its pipeline, supported by a relatively clean, low‑debt balance sheet but an obvious need for periodic capital raises. Strategically, its differentiation comes from a muscle‑centric platform and oral small molecules that could complement or compete with gene‑focused therapies. The opportunity is significant if pivotal trials confirm meaningful clinical benefit, but uncertainty is high, timelines are long, and outcomes are heavily dependent on a small number of key studies over the next few years.

NEWS

November 20, 2025 · 8:00 AM UTC

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Read more

November 12, 2025 · 8:00 AM UTC

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Read more

November 10, 2025 · 8:00 AM UTC

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

Read more

November 7, 2025 · 8:00 AM UTC

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Read more

November 6, 2025 · 8:00 AM UTC

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Read more